|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 473/32 | (2006.01) |
| C07D 473/32 | (2013.01) | ||
| A61K 31/522 | (2006.01) | ||
| A61P 35/00 | (2018.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3807278 |
| (13) | Kind of document | T |
| (96) | European patent application number | 19734289.2 |
| Date of filing the European patent application | 2019-06-14 | |
| (97) | Date of publication of the European application | 2021-04-21 |
| (45) | Date of publication and mention of the grant of the patent | 2022-08-31 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2019/065686 |
| Date | 2019-06-14 |
| (87) | Number | WO 2019/238929 |
| Date | 2019-12-19 |
| (30) | Number | Date | Country code |
| 201862685325 P | 2018-06-15 | US |
| (72) |
FINLAY, Maurice, Raymond, Verschoyle , GB
GOLDBERG, Frederick, Woolf , GB
HOWARD, Martin, Richard , GB
TING, Attilla, Kuan, Tsuei , GB
|
| (73) |
Astrazeneca AB ,
151 85 Södertälje,
SE
CANCER RESEARCH TECHNOLOGY LIMITED , Angel Building 407 St. John Street, London EC1V 4AD, GB |
| (54) | PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER |
| PURINONE DERIVATIVES AND THEIR USE IN TREATING CANCER |